Rialto Markets
08/03/2022
08/03/2023
$580
$50,000,000
$580
Equity – Common
RegA+
Series A
$5.80
$291,787,299
Lynnwood, Washington
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Growth
Kurve Therapeutics is raising funds through Reg A+ crowdfunding with Rialto Markets as the Broker-Dealer. The company has developed its patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology. The technology creates a focused flow through the curved pathways of the nasal cavity and allows access to the olfactory region to treat neurogenerative diseases. Kurve Therapeutics’ technology has been featured in multiple publications and has completed Phase II studies on Alzheimer’s patients. Marc Giroux, Tom McDowell, and Glenn Cornett founded Kurve Therapeutics in 2019. The current crowdfunding campaign has a maximum target of $50,000,000. The campaign proceeds will be used for asset purchase, marketing, clinical studies, contract manufacturing, and working capital.
Balance Sheet
|
Cash and Cash Equivalents |
$373,804 |
|
Accounts and Notes Receivable |
$15,000 |
| Total Assets |
$640,574 |
|
Accounts Payable & Accrued Liabilities |
$28,331 |
|
Long Term Debt |
$507,500 |
|
Total Liabilities |
$606,726 |
|
Total Stockholders’ Equity |
$33,848 |
| Total Liabilities and Equity |
$640,574 |
Statement of Comprehensive Income Information
|
Total Revenues |
$70,700 |
|
Costs & Expenses Applicable to Rev |
$128,344 |
| Net Income |
$-65,427 |
|
Earnings Per Share – Basic |
$0.00 |
|
Earnings Per Share – Diluted |
$0.00 |
Auditor: Assurance Dimensions
Financials as of: 08/03/2022
